Oncocyte Profit Margin

Oncocyte (OCX) currently reports a profit margin of -24.55% as of March 2026. That compares with -15.15% in the prior-year period — down 62.1% year over year. That is below the Technology sector average of 36.35%. Use the charts on this page to explore Oncocyte's profit margin history and peer comparisons.

Oncocyte's profit margin decreased from -15.15% to -24.55% — a 62.1% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Oncocyte's profit margin of -24.55% is lower than the Technology sector average of 36.35%. That is roughly 6852.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Oncocyte's current -24.55% should be judged against Technology norms (sector average: 36.35%) and against OCX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -24.55%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Technology average is 36.35%. From there, open related valuation or income-statement pages for Oncocyte, and consider following OCX for alerts when major investors trade the stock.